Abstracts tagged "Gene Expression"

Abstract Number: 2657 • 2017 ACR/ARHP Annual Meeting
Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established Systemic Lupus Erythematosus (SLE)-Risk Loci in Lupus Patient Monocytes
Yogita Ghodke-Puranik¹, Zhongbo Jin², Wei Fan³, Mark A. Jensen¹, Jessica M. Dorschner², Danielle Vsetecka², Shreyasee Amin⁴, Ashima Makol⁵, Floranne C. Ernste⁶, Thomas Osborn⁴, Kevin Moder⁴, Vaidehi Chowdhary⁷ and Timothy Niewold⁸, ¹Colton Center for Autoimmunity, New York University, New York, NY, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, China, Shanghai, China, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁶Division of Rheumatology, Mayo Clinic Rochester, Rochester, MN, ⁷Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁸New York University, New York, NY
Background/Purpose: Most confirmed SLE-risk loci are found near or in genes with immune function, yet how these loci influence diverse immune cell subsets remains unknown.…
Abstract Number: 297 • 2017 ACR/ARHP Annual Meeting
Multiplexed Characterization of Circulating and Joint-Derived Human Neutrophils in Inflammatory Arthritis
Ricardo Grieshaber Bouyer¹, Olha Halyabar², Anais Levescot¹, Kacie Hoyt², Lauren Henderson² and Peter Nigrovic^1,2, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Neutrophils are innate immune cells that play a central role in the initiation of inflammatory arthritis as well as mediating tissue damage. We sought…
Abstract Number: 1416 • 2017 ACR/ARHP Annual Meeting
Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis. a Retrospective Study with 14 Years of Follow-up
Andrea Cuervo¹, Raquel Celis², Julio Ramírez³, Alicia Usategui⁴, Regina Faré⁵, M. Victoria Hernández⁶, Virginia Ruiz-Esquide³, Jose Inciarte-Mundo⁷, Raimon Sanmarti⁸, Jose L. Pablos⁹ and Juan D. Cañete⁷, ¹Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁶Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁷Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁸Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Undifferentiated Arthritis (UA) is defined as an inflammatory oligo/poly arthritis that does not fulfil criteria for a definitive diagnosis.Delay in diagnosis and treatment leads…
Abstract Number: 2659 • 2017 ACR/ARHP Annual Meeting
Development of a Protocol for Single Cell Transcriptomics of Cells from Cryopreserved Lupus Nephritis Kidney Tissue and Urine for the Accelerating Medicines Partnership RA/SLE Network
Deepak Rao¹, Celine C. Berthier², Arnon Arazi³, Anne Davidson⁴, Yanyan Liu⁵, Edward Browne³, Thomas Eisenhaure³, Adam Chicoine⁶, David Lieb³, Dawn Smilek⁷, Patti Tosta⁷, James Lederer⁸, Michael Brenner⁵, David Hildeman⁹, E. Steve Woodle¹⁰, David Wofsy¹¹, Jennifer H. Anolik¹², Matthias Kretzler¹³, Nir Hacohen¹⁴ and Betty Diamond¹⁵, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ³Broad Institute, Cambridge, MA, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Immune Tolerance Network, San Francisco, CA, ⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹University of Cincinnati, Cincinnati, OH, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Rheumatology, UCSF, San Francisco, CA, ¹²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ¹³Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, ¹⁴Harvard Medical School, Boston, MA, ¹⁵Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: There is a critical need to define the cells that mediate tissue damage in lupus nephritis. Here we aimed to establish a protocol to…
Abstract Number: 405 • 2017 ACR/ARHP Annual Meeting
Dynamics of Transcriptional Signatures from Purified Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
Philip J. Homan, Salina Dominguez, Harris Perlman, Deborah R. WInter and Carla Cuda, Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) manifests in persistent synovial inflammation, cellular infiltration and pro-inflammatory cytokine production, resulting in progressive joint destruction. Macrophages have been implicated in…
Abstract Number: 1658 • 2017 ACR/ARHP Annual Meeting
Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways
Rufei Lu¹, Cristina Arriens², Teresa Aberle³, Stan Kamp³, Melissa E. Munroe³, Tim Gross¹, Wade DeJager³, Susan Macwana³, Virginia C. Roberts³, Stephen Apel⁴, Hua Chen³, Eliza Chakravarty⁵, Katherine Thanou³, Joan T. Merrill⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical research af, Edmond, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose : Interferon (IFN) pathways are dysregulated in a subset of patients with systemic lupus erythematosus (SLE). IFN dysregulation likely contributes to SLE pathogenesis and…
Abstract Number: 2866 • 2017 ACR/ARHP Annual Meeting
Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study
Paul Emery¹, Peter C. Taylor², Michael Weinblatt³, Yoshiya Tanaka⁴, Edward C. Keystone⁵, Ernst R. Dow⁶, Richard Higgs⁶, William L. Macias⁶, Guilherme Rocha⁶, Terence P. Rooney⁶, Douglas E. Schlichting⁶, Steven H. Zuckerman⁶ and Iain B. McInnes⁷, ¹Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ²NDORMS, University of Oxford, Oxford, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵University of Toronto, Toronto, ON, Canada, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In RA-BEAM (NCT01710358), baricitinib (BARI), an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, yielded significant improvements in patients (pts) with…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…
Abstract Number: 1668 • 2017 ACR/ARHP Annual Meeting
Identification of a Serum Measure of Lupus Nephritis Activity That Detects Molecular Pathways and Mechanisms Implicated in Renal Damage
Mikhail Olferiev¹, Dina Greenman², David Fernandez¹, Kerry Merritt¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Up to 60% of SLE patients develop renal involvement, and renal injury is an important predictor of mortality in patients with SLE. Kidney biopsy…
Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
O Jabado¹, MA Maldonado¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴, William H. Robinson⁵, A Greenfield¹ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴Metroplex Clinical Research Center Dallas, Dallas, TX, ⁵Stanford University, Palo Alto, CA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…
Abstract Number: 128 • 2017 Pediatric Rheumatology Symposium
Treatment Response in Polyarticular Juvenile Idiopathic Arthritis is Associated With Transcriptional Changes and Chromatin Reorganization in CD4+ T cells
Evan Tarbell¹, Kaiyu Jiang², Yanmin Chen², Tao Liu³ and James Jarvis⁴, ¹Biochemistry, University at Buffalo, Buffalo, NY, ²Pediatrics, University at Buffalo, Buffalo, NY, ³Department of Biochemistry, University at Buffalo, Buffalo, NY, ⁴Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: The polyarticular form of JIA is associated with well-documented transcriptional abnormalities in peripheral blood cells. The abnormalities can be observed in neutrophils, peripheral blood…
Abstract Number: 140 • 2017 Pediatric Rheumatology Symposium
Modular Gene Expression Discrimination of Juvenile Idiopathic Arthritis and Inflammatory Bowel Disease Subphenotypes in Peripheral Blood
Urko Marigota¹, Angela Mo¹, Jarod Prince², Lai Hin Kimi Chan³, Subramaniam Kugathasan², Greg Gibson¹ and Sampath Prahalad⁴, ¹Center for Integrative Genomics, Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁴Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases which have in common inflammatory arthritis, but distinct clinical and genetic associations. Using biological…
Abstract Number: 138 • 2017 Pediatric Rheumatology Symposium
Modeling Transcriptional Rewiring in Neutrophils through the Course of Treated Juvenile Idiopathic Arthritis
Zihua Hu¹, Kaiyu Jiang², Mark B. Frank³, Yanmin Chen² and James Jarvis⁴, ¹Center for Computational Research, University at Buffalo, Buffalo, NY, ²Pediatrics, University at Buffalo, Buffalo, NY, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY
Background/Purpose: We have previously shown that neutrophils in children with polyarticular juvenile idiopathic arthritis (JIA) display abnormal transcriptional patterns linked to fundamental metabolic derangements. These…
Abstract Number: 137 • 2017 Pediatric Rheumatology Symposium
Chromatin Landscapes and Genetic Risk For Juvenile Idiopathic Arthritis
James Jarvis¹, Lisha Zhu², Lai Ping Wong³, Tao Liu⁴, Kaiyu Jiang³ and Yanmin Chen³, ¹Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY, ²Biochemistry, University at Buffalo, Buffalo, NY, ³Pediatrics, University at Buffalo, Buffalo, NY, ⁴Department of Biochemistry, University at Buffalo, Buffalo, NY
Background/Purpose: The transcriptomes of peripheral blood cells in children with juvenile idiopathic arthritis (JIA) show distinct transcriptional aberrations that suggest impairment of transcriptional regulation. To…
Abstract Number: 8 • 2017 Pediatric Rheumatology Symposium
Examination of Reported Risk Loci from Candidate Gene Studies of Systemic Juvenile Idiopathic Arthritis Identifies Link between IL1RN Variation and both Disease Susceptibility and Response to Interleukin-1 Directed Therapy
Victoria Arthur¹, Emily Shuldiner¹, Anne Hinks², The International Childhood Arthritis Genetics (INCHARGE) Consortium³, Patricia Woo⁴, Wendy Thomson², Elaine F. Remmers⁵ and Michael J. Ombrello¹, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³INCHARGE Consortium, Bethesda, MD, ⁴Paediatric Rheumatology Unit, University College London, London, United Kingdom, ⁵Inflammatory Disease Section, NHGRI, NIH, Bethesda, MD
Background/Purpose: Systemic JIA (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses to treatment.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].